What’s the Valneva vax that’s supposed to be ‘variant proof’?
A COVID-19 vaccine from French company Valneva has yet to complete clinical trials. But it has caught the eye of governments in the UK, Europe and Australia.
One of the vaccine’s main selling points is its apparent ability to mount a more general immune response against SARS-CoV-2, the virus that causes COVID-19, rather than rely on the spike protein to do this.
